Miralles Gines Diego sold $4K of ARTV
Miralles Gines Diego (President & Head of R&D) sold 1,043 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 on 2026-11-17.
How this was made
The 30-second read
Why it matters
The filing provides incremental information about insider selling activity but does not include guidance, trial results, financing, or regulatory actions.
Market read
Traders may note insider selling, but the disclosed transaction value is small and is unlikely to drive a material repricing by itself.
What to watch
Insider sales often reflect routine diversification, tax planning, or personal liquidity, and Form 4 does not reveal intent beyond the transaction details.
Background
The article is a SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc.
Ticker impact
Artiva Biotherapeutics disclosed an insider open-market sale by its President and Head of R&D of 1,043 shares at $3.9119 on 2026-11-17.
Likely limited downside pressure or no sustained move as the transaction size is modest and lacks a stated 10b5-1 plan.
Form 4 insider sales can be interpreted as liquidity or diversification; here the disclosed value is about $4.1k and there is no indication of a broader corporate event.
Market effects
No clear sector read-through from a single small insider sale at a biotech.
None.
None.
Counterpoint
The absence of a 10b5-1 plan could be viewed as more discretionary selling, but the dollar amount is too small to be a strong signal.
Key entities
- issuerArtiva Biotherapeutics, Inc.
US-listed biotech subject of the Form 4 insider sale disclosure.
- insiderMiralles Gines Diego
President and Head of R&D who sold 1,043 shares in an open-market transaction.



